# Examining the Ability of Herpes Simplex Virus Type 2 (HSV2) Therapy to Reduce HIV Target Cell Numbers in the Cervix

> **NCT00946556** · NA · COMPLETED · sponsor: **University of Toronto** · enrollment: 30 (actual)

## Conditions studied

- Herpes Simplex Type Two Infection
- HIV Infections

## Interventions

- **DRUG:** Valacyclovir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00946556
- **Lead sponsor:** University of Toronto
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2012-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00946556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00946556, "Examining the Ability of Herpes Simplex Virus Type 2 (HSV2) Therapy to Reduce HIV Target Cell Numbers in the Cervix". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00946556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*